This study is currently not recruiting participants.

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to provide an investigational treatment regimen of Daclatasvir plus Sofosbuvir used in combination for 24 weeks in post-liver transplant subjects who have recurrent chronic Hepatitis C Virus (HCV) infection who have a serious or life-threatening condition.

Description

The purpose of this study is to provide daclatasvir (DCV) for 24 weeks to be given in combination with sofosbuvir(SOF) to post-liver transplant subjects with chronic hepatitis C recurrence and who have a serious or immediately life-threatening condition, or experienced an event that has decreased their life expectancy to

Details
Condition hepatitis
Age 18years - 100years
Clinical Study IdentifierTX4156
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.